Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

Table 2 Compliance and persistence measures of users naïve to disease-modifying agents

	Fingolimod	Interferon beta-1b		Intramuscular interferon beta-1a		Subcutaneous interferon beta-1a		Glatiramer acetate
	N=96	N=167		N=313		N=257		N=592
			p-value		p-value		p-value		p-value
PDC: mean (SD)	0.80 (0.23)	0.65 (0.31)	<0.0001	0.72 (0.30)	0.0027	0.67 (0.31)	<0.0001	0.72 (0.29)	0.0017
PDC Categories (%)			0.0003		0.0347		0.0043		0.0127
0-<0.2	3.13	11.38		8.63		13.62		6.93
0.2-<0.4	7.29	16.77		10.86		12.45		11.49
0.4-<0.6	4.17	12.57		10.54		8.95		13.51
0.6-<0.8	18.75	17.37		18.53		15.56		14.02
0.8-1	66.67	41.92		51.44		49.42		54.05
MPR: mean (SD)	0.90 (0.09)	0.86 (0.17)	0.0055	0.88 (0.16)	0.0502	0.88 (0.15)	0.0551	0.89 (0.15)	0.1769
MPR Categories (%)			0.0349		0.1255		0.3037		0.2619
0-<0.2	0.00	0.62		0.68		0.41		0.36
0.2-<0.4	0.00	1.85		1.69		1.24		1.79
0.4-<0.6	1.05	8.02		6.78		4.96		5.02
0.6-<0.8	11.58	16.67		11.53		13.22		11.29
0.8-1	87.37	72.84		79.32		80.17		81.54
Persistence (<60 day gap) (%)	68.75	46.11	0.0004	53.67	0.0090	55.25	0.0218	56.25	0.0213
Persistent days (days till first 60-day gap) (%)
No gap	68.75	46.11		53.67		55.25		56.25
1-90	6.25	16.77		14.38		18.68		13.68
91-180	9.38	14.37		10.22		12.06		11.82
181-270	8.33	14.37		13.74		8.56		10.98
270+	7.29	8.38		7.99		5.45		7.26
Switched to other DMTs after discontinuation (%)	1.04	13.17	0.0008	7.99	0.0147	11.67	0.0017	7.77	0.0153

P-values based on comparison with fingolimod cohort, using Chi-square tests for categorical variables and Student’s t-tests for continuous variables.
DMT: disease-modifying therapy. SD: standard deviation. PDC: proportion of days covered. MPR: medication procession ratio.

ISSN: 1471-2377